Propylone

Propylone
Clinical data
Other names	3,4-Methylenedioxy-N-propylcathinone; MD-PrC; PrONE; bk-3,4-MDPA
Drug class	Monoamine releasing agent; Monoamine reuptake inhibitor
Identifiers
	IUPAC name 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one;
CAS Number	201474-93-3;
PubChem CID	85764579;
ChemSpider	129433781;
UNII	TBJ4S8YF37;
CompTox Dashboard (EPA)	DTXSID901342656 ;
Chemical and physical data
Formula	C13H17NO3
Molar mass	235.283 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCNC(C)C(=O)C1=CC2=C(C=C1)OCO2;
	InChI InChI=1S/C13H17NO3/c1-3-6-14-9(2)13(15)10-4-5-11-12(7-10)17-8-16-11/h4-5,7,9,14H,3,6,8H2,1-2H3; Key:YFVKHKCZBSGZPE-UHFFFAOYSA-N;

Propylone, also known as 3,4-methylenedioxy-N-propylcathinone is a mixed monoamine releasing agent and reupake inhibitor of the cathinone family related to methylone and ethylone.^[1]

Other names3,4-Methylenedioxy-N-propylcathinone; MD-PrC; PrONE; bk-3,4-MDPA

Quick facts Clinical data, Other names ...

Close

It acts specifically as a weak partial serotonin–dopamine releasing agent (SDRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), with EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) values for induction of monoamine release of 3,128 nM (30%) for serotonin and 976 nM (20%) for dopamine, and IC₅₀Tooltip half-maximal inhibitory concentration value for monoamine reuptake inhibition of 2,462 nM for serotonin, 28,540 nM for norepinephrine, and 1,863 nM for dopamine.^[1]

The drug was first described in the literature in a 1996 patent by Alexander Shulgin and Peyton Jacob III.^[2] It was subsequently characterized more thoroughly by 2015^[1] and was encountered as a novel designer drug in Europe by 2016.^[3]^[4]^[5]

See also